Cash provided by financing activities was $28.3 million for the nine months ended July 31, 2023, which related principally to net receipts on our credit facilities totaling $35.6 million (net of repayment of Calavo;s previously existing Revolving Credit Facility with Bank of America, N.A. (the “Existing Credit Facility”) of $34.9 million) and the receipt of $3.5 million from our Term Loan with Wells Fargo, partially offset by payments of $8.7 million in dividends, payments on long-term obligations of $1.4 million and payments on debt issuance costs of $0.7 million.
Our principal sources of liquidity are our existing cash reserves, cash generated from operations and amounts available for borrowing under our existing credit facilities. Cash and cash equivalents as of July 31, 2023 and October 31, 2022 totaled $2.2 million and $3.1 million. Our working capital at July 31, 2023 was $49.1 million, compared to $23.7 million at October 31, 2022.
We believe that cash flows from operations, the available Credit Facility, and other sources will be sufficient to satisfy our future capital expenditures, grower recruitment efforts, working capital and other financing requirements for the foreseeable future.
On June 26, 2023, Calavo and certain subsidiaries entered into a Credit Agreement by and among, Calavo, certain subsidiaries of Calavo as guarantors, and Wells Fargo Bank, National Association, as agent and lender. The Credit Agreement provides for a revolving credit facility of up to $90.0 million, along with an undrawn capex credit facility of up to $10.0 million.
The initial proceeds of the Revolving Loans were used to repay all outstanding amounts under Calavo’s previous revolving credit faciilty with Bank of America, N.A. and to pay related transaction fees and expenses, and following the Closing Date may be used for working capital and other general corporate purposes. For a period of one year following the Closing Date, Calavo may utilize the proceeds of the Term Loan to pay a certain percentage of the costs of certain equipment purchased by Calavo.
Borrowings of the Revolving Loans under the Credit Agreement are asset based and will be subject to a borrowing base calculation that includes a certain percentage of eligible accounts receivable, inventory and equipment of Calavo, less any reserves implemented by Agent in its permitted discretion; provided that the equipment based portion of such borrowing base calculation will reduce monthly following the Closing Date.
Borrowings under the Credit Agreement bear interest at a rate per annum equal to an applicable margin, plus, at Calavo’s option, either a base rate or a secured overnight financing rate (“SOFR”) term rate (which includes a spread adjustment of 0.10% and is subject to a floor of 0.00%). The applicable margin is (i) for Revolving Loans, 0.50% for base rate borrowings and 1.50% for SOFR term rate borrowings, and (ii) for Term Loan, 1.00% for base rate borrowings and 2.00% for SOFR term rate borrowings. The New Credit Facility matures on June 26, 2028.
As of July 31, 2023, we were in compliance with the financial covenants. As of July 31, 2023, approximately $41.7 million was available for borrowing, based on our borrowing base calculation discussed above.
The weighted-average interest rate under the New Credit Facility was 6.7% at July 31, 2023. Under the Credit Facility, we had $36.8 million and $3.5 million outstanding related to the Revolving Loans and Term Loan, respectively, as of July 31, 2023.
Contractual Commitments
There have been no other material changes to our contractual commitments from those previously disclosed in our Annual Report on Form 10-K for our fiscal year ended October 31, 2022. For a summary of the contractual commitments at October 31, 2022, see Part II, Item 7, in our 2022 Annual Report on Form 10-K.